Zinc (?)-immune pediatric virucidal activities for 2019-nCoV prevention and therapeutic effects of COVID-19 bronchitis and pneumonia

Abstract

Zinc (Ⅱ)-immune pediatric virucidal activities for children with 2019-nCoV prevention and COVID-19 bronchitis and pneumonia are discussed, and these Zn2+-immune pediatric virucidal effects result in the following. Zinc intakes by zinc induced immunity are required 3 mg/day for 7 month to 3 years, 5 mg/day for 4～ 8 years, and 8 mg/day for 9 ～13 years in children. Zinc supplementation have been assessed, from 15 mg to 140 mg/week, with the upper range exceeding the recommended daily infection (RDI) for children of 2 mg/day for children less than one year of age and up to 7 mg/day for children between 1 to 3 years. Zinc induced pediatric preventing respiratory 2019-nCoV is required that supplementation with zinc gluconate 20 mg in Zn deficient children resulted in a nearly twofold reduction of acute lower respiratory infections as well as the time to recovery. Zinc supplementation in children is associated with a reduction in the incidence and prevalence of pneumonia. Preventing 2019-nCoV pneumonia is required that zinc supplementation alone (10 to 20 mg) for more than 3 months significantly reduces in the rate of pneumonia. Prophylactic zinc supplementation for two weeks may reduce the morbidity due to acute lower respiratory infections. Zinc gluconate supplement may result in significant reduction in respiratory morbidity among children with acute lower respiratory infections. In addition. as serum zinc level of Acute Respiratory Infection (ARI)-children was very low, higher zinc concentration treatments as low sociodemographic factors, poor nutritional status and male children were prevalently associated with higher incidence of acute respiratory infections. Adjuvant treatment with 20 mg zinc/day accelerates recovery from severe pneumonia in children. Primary outcome was recovery from pneumonia and 30 mg/day of zinc supplementation reduces pneumonia in children with chronic kidney disease (CKD). Zinc supplementation + Chloroquine (CQ)/hydroxychloroquine (HCQ) may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. The serum zinc level returned to a normal level (median, 53.20 μmol/L) on day 12±2 in the treatment. There was no statistical difference in the pediatric critic illness score, lung injury score, length of hospital stay, and duration of mechanical ventilation between the zinc treatments. The oxidative stress in pediatric diseases causes an oxidative burst that results in a respiratory burst and rapid ROS production. Thus, zinc pediatric intake may be required to be effective range 10～20 mg/d for 2019-CoV prevention, 10～30 mg/d for reduction of COVID-19 bronchitis, and 20～30 mg/d for recovery from COVID-19 pneumonia, in which Zn2+ could bind with viral surface proteins by Zn2+ions-centered tetrahedrally coordination pattern.